GCG and neoplasm: Experimental data have suggested beneficial effects of GLP-1 RAs in colorectal, prostate, gall bladder, ovarian, and endometrial cancers, with studies reporting reduced tumour cell viability, impaired metastatic potential, and enhanced sensitivity to other therapeutic agents.